Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Abcellera Biologics Inc
(NQ:
ABCL
)
2.610
+0.100 (+3.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Abcellera Biologics Inc
< Previous
1
2
3
4
Next >
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023
May 29, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Partners with the Governments of Canada and British Columbia to Advance Drug Development Capabilities and Infrastructure that Will Accelerate Innovative Medicines to Patients
May 24, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q1 2023 Business Results
May 04, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Presents New Data on T-Cell Engager Platform at AACR 2023
April 17, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25, 2023
April 11, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report First Quarter 2023 Financial Results on May 4, 2023
April 06, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and RQ Bio Partner to Accelerate the Advancement of New Therapies for Infectious Disease
March 22, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Two Presentations on T-Cell Engager Discovery at AACR 2023
March 14, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the Cowen 43rd Annual Health Care Conference on March 6, 2023
February 23, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Full Year 2022 Business Results
February 21, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023
February 01, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Full Year 2022 Financial Results on February 21, 2023
January 24, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture Patent
January 19, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023
January 04, 2023
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and AbbVie Partner to Advance New Antibody Therapies
December 15, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare Diseases
December 01, 2022
From
Rallybio Corporation
Via
Business Wire
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022
November 10, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q3 2022 Business Results
November 08, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Present at Upcoming Investor Conferences in November
November 04, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera’s First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development
November 02, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022
October 11, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022
October 05, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic
September 21, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q2 2022 Business Results
August 09, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients
August 03, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies
July 27, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022
July 12, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options
June 29, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera Reports Q1 2022 Business Results
May 10, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration
May 03, 2022
From
AbCellera Biologics Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.